Beacon Therapeutics
London, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $341M
Overview
Developing adeno-associated virus (AAV) gene therapies for inherited retinal diseases.
OphthalmologyRare Disease
Technology Platform
Utilizes adeno-associated virus (AAV) vectors engineered for targeted delivery of therapeutic genes to specific retinal cell types.
Funding History
3Total raised:$341M
Venture$75M
Series B$170M
Venture$96M
Opportunities
Success in XLRP, a leading cause of blindness in young men, could establish a beachhead for a broader ophthalmology gene therapy franchise.
Risk Factors
Faces clinical development risks specific to gene therapy, including immune responses to the AAV vector and demonstrating durable efficacy.
Competitive Landscape
Competes in the inherited retinal disease space with companies like Spark Therapeutics, MeiraGTx, and Biogen (which previously partnered on the lead asset).